<SEC-DOCUMENT>0001140361-24-003756.txt : 20240125
<SEC-HEADER>0001140361-24-003756.hdr.sgml : 20240125
<ACCEPTANCE-DATETIME>20240125080015
ACCESSION NUMBER:		0001140361-24-003756
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240124
FILED AS OF DATE:		20240125
DATE AS OF CHANGE:		20240125

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			InflaRx N.V.
		CENTRAL INDEX KEY:			0001708688
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38283
		FILM NUMBER:		24558607

	BUSINESS ADDRESS:	
		STREET 1:		WINZERLAER STR. 2
		CITY:			JENA
		STATE:			2M
		ZIP:			07745
		BUSINESS PHONE:		49 3641 508180

	MAIL ADDRESS:	
		STREET 1:		WINZERLAER STR. 2
		CITY:			JENA
		STATE:			2M
		ZIP:			07745

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Fireman B.V.
		DATE OF NAME CHANGE:	20170606
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ef20019467_6k.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit Financial
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 14pt; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
      <div style="color: rgb(0, 0, 0); font-weight: bold;"> <br>
      </div>
      <div><font style="color: #000000;"> </font>
        <hr noshade="noshade" align="center" style="height: 2px; width: 20%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
    <div><br>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 18pt; font-weight: bold;">FORM 6-K</div>
      <div style="color: rgb(0, 0, 0); font-weight: bold;"> <br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; width: 20%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div><br>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">PURSUANT TO RULE 13A-16 OR 15D-16 UNDER</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">THE SECURITIES EXCHANGE ACT OF 1934</div>
      <div><font style="color: #000000;"> </font><br>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;">For the month of January 2024</div>
      <div><font style="color: #000000;"> </font><br>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;">Commission File Number: 001-38283</div>
      <div style="color: rgb(0, 0, 0); font-weight: bold;"> <br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; width: 20%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div><br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 24pt; font-weight: bold;">InflaRx N.V.</div>
      <div style="text-align: center; color: #000000;">(Translation of registrant's name into English)</div>
      <div style="color: rgb(0, 0, 0);"> <br>
      </div>
      <div style="text-align: center;"><font style="color: #000000;"> </font>
        <hr noshade="noshade" align="center" style="height: 2px; width: 20%; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;"></div>
      <br>
      <div style="text-align: center; color: #000000; font-weight: bold;">Winzerlaer Str. 2</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">07745 Jena, Germany</div>
      <div style="text-align: center; color: #000000;">(Address of principal executive office)</div>
      <div style="color: rgb(0, 0, 0);"> <br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; width: 20%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div><br>
      </div>
      <div style="text-align: center; color: #000000;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
      <div><font style="color: #000000;"> </font><br>
      </div>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z7ef188582b2c4ed69bb775fb0c0704e2">

          <tr>
            <td style="width: 48%;">
              <div style="text-align: right;">&#160;Form 20-F &#9746;</div>
            </td>
            <td style="width: 4%;"><br>
            </td>
            <td style="width: 48%;">
              <div>Form 40-F &#9744;</div>
            </td>
          </tr>

      </table>
      <div style="color: rgb(0, 0, 0);"> <br>
      </div>
      <div>
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><font style="color: #000000;"> </font></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%-->
      <div style="text-align: center; color: #000000; font-weight: bold;">EXPLANATORY NOTE</div>
      <div><font style="color: #000000;"> </font><br>
      </div>
      <div style="color: #000000;">On January 25, 2024, InflaRx N.V. (the &#8220;Company&#8221;) issued a press release titled &#8220;InflaRx Announces Initiation of its Commitment Program for GOHIBIC&#174; (vilobelimab) to Help Broaden Access for Eligible Patients.&#8221; A copy of
        the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">2</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;">EXHIBIT INDEX</div>
      <div><font style="color: #000000;"> </font><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z859390ce56ae47239cefa8027d23e17a" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 20%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Exhibit No.</div>
            </td>
            <td style="width: 80%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Description</div>
            </td>
          </tr>
          <tr>
            <td style="width: 20%; vertical-align: top;">
              <div><a href="ef20019467_ex99-1.htm">99.1</a></div>
            </td>
            <td style="width: 80%; vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0);">Press Release, dated January 25, 2024</div>
            </td>
          </tr>

      </table>
      <div><font style="color: #000000;"> </font><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">3</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;">SIGNATURES</div>
      <div><font style="color: #000000;"> </font><br>
      </div>
      <div style="color: #000000;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>
      <div><font style="color: #000000;"> </font><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="zc15d1ae79fce4021b3ecbcedd4d58004" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;"><br>
            </td>
            <td style="vertical-align: top;" colspan="2">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">INFLARX N.V.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;"><br>
            </td>
            <td style="vertical-align: top;" colspan="2"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Date: January 25, 2024</div>
            </td>
            <td style="width: 5%; vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0);">By:</div>
            </td>
            <td style="width: 44.57%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: rgb(0, 0, 0);">/s/ Niels Riedemann</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;"><br>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Name:</div>
            </td>
            <td style="width: 44.57%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Niels Riedemann</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;"><br>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Title:</div>
            </td>
            <td style="width: 44.57%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Chief Executive Officer</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">4</font></div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ef20019467_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit Financial
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div>
    <div style="text-align: right; margin-right: 3.7pt; margin-left: 17.85pt; font-weight: bold;">Exhibit 99.1</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-right: 3.6pt;"><img width="149" height="47" src="image0.jpg"></div>
    <div style="text-align: center; margin-right: 3.7pt; margin-left: 17.85pt;"> <br>
    </div>
    <div style="text-align: center; margin-right: 3.7pt; margin-left: 17.85pt;">InflaRx Announces Initiation of its Commitment Program for GOHIBIC<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>(vilobelimab) to Help Broaden Access for Eligible Patients</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zeb760922acdb46b7a32606c5855645a7" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 17.85pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-style: italic;">InflaRx to cover costs of GOHIBIC for patients who are treated in line with its Emergency Use Authorization (EUA) but do not survive.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z9165ac58d5534af2b94e3b443ad9187b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 17.85pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-style: italic;">InflaRx is determined to support broader access to GOHIBIC for eligible patients.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify;"><font style="font-weight: bold;">Ann Arbor, USA, January 25, 2024 </font>&#8211; InflaRx Pharmaceuticals Inc., a subsidiary of InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory
      therapeutics by targeting the complement system, announced today that the Company has launched <u>The InflaRx Commitment Program</u>&#160; (Commitment Program). Pursuant to the Commitment Program, the cost of GOHIBIC (vilobelimab) will be refunded for up
      to six (6) administered inpatient doses (the full treatment course) to institutions that meet the eligibility requirements*, for patients who were administered GOHIBIC in line with its EUA and who died due to COVID-19 in the intensive care unit.</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-right: 3.6pt;">In April 2023, the U.S. Food and Drug Administration (FDA), issued an EUA for GOHIBIC for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of the patient receiving
      invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO). While GOHIBIC has been FDA authorized, it is not FDA approved for this use.</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-right: 3.6pt;">The Commitment Program is designed to encourage medical facilities across the United States to stock GOHIBIC, since the initiation of treatment is time critical, and to ultimately provide the
      opportunity for patients to access this potentially life-saving therapy.</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-right: 3.6pt;">According to the Centers for Disease Control, there has been a recent increase in COVID-19 fatality rates, with reported deaths related to this disease in the range of 1,500 deaths per week in the
      U.S.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup></div>
    <div>&#160;</div>
    <div>
      <hr noshade="noshade" align="left" style="height: 2px; width: 25%; color: #000000; background-color: #000000; margin-left: 0px; margin-right: auto; border: none;"></div>
    <div style="text-align: justify; text-indent: -5.65pt; margin-right: 5.65pt; margin-left: 5.65pt;">* Eligibility Requirements, Terms and Conditions apply. Please see the full Terms and Conditions provided on the webpage: <u>The InflaRx Commitment
        Program</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: -18pt; margin-right: 3.6pt; margin-left: 18pt;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup>&#160;<u>Centers for Disease Control and Prevention. COVID data tracker</u>.</div>
    <div style="text-align: justify; text-indent: -18pt; margin-right: 3.6pt; margin-left: 18pt;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: justify; margin-right: 3.6pt;"><img width="149" height="47" src="image0.jpg"></div>
        </div>
      </div>
    </div>
    <div style="text-align: justify; margin-right: 3.6pt;">Christian Sandrock, M.D., M.P.H., FCCP, Division Vice Chair of Internal Medicine, Director of Critical Care, Professor of Medicine, UC Davis Health, said &#8220;<font style="font-style: italic;">Once a
        patient with COVID-19 reaches the point of intubation, there are extremely limited treatments available outside of supportive care and mechanical ventilatory support.&#160; With COVID-19 deaths again on the rise, it is critical that doctors have access
        to more therapies to help save the lives of these patients, particularly for those that have progressed to require mechanical ventilation. With the emergency use authorization of GOHIBIC, the FDA recognized a critical unmet need and provided those
        of us on the frontlines, fighting this disease, an important new option which has been specifically developed as a potentially life-saving therapy for these sickest patients.&#8221;</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-right: 3.6pt;">He added: <font style="font-style: italic;">&#8220;Many hospitals struggle to provide patient access to all available medicines, even those that may be lifesaving. So, it is reassuring that InflaRx is
        willing to reimburse the cost of their medicine in cases where the patient does not survive. This shows me that InflaRx is confident in their product, are doing everything they can to support hospitals and get GOHIBIC to patients who are in
        critical need of intervention.&#8221;</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-right: 3.6pt;">Prof. Niels C. Riedemann, Chief Executive Officer, and Founder of InflaRx, commented: <font style="font-style: italic;">&#8220;COVID-19 continues to take far too many lives. Despite this unacceptable
        situation, patients do not always have access to approved or authorized treatment options. With today&#180;s announcement, we are demonstrating our strong commitment to help make GOHIBIC available for the most affected COVID-19 patients as a potential
        life-saving therapy. There are currently no approved or authorized alternatives to GOHIBIC, and we believe that all eligible patients and the physicians responsible for their care should have access to this treatment.&#8221;</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-right: 3.6pt;">The data supporting the EUA for GOHIBIC was based on a multicenter Phase III (PANAMO) trial, one of the largest 1:1 randomized, double-blind placebo-controlled trials in invasively mechanically
      ventilated COVID-19 patients in intensive care units. The results showed that treatment with GOHIBIC improved survival, with a relative reduction in 28-day all-cause mortality of 23.9% compared to placebo in the global data set. The data has been
      published in <u>The Lancet Respiratory Medicine</u>. GOHIBIC is the only drug directed against the complement factor C5a that is authorized for the treatment of certain critically ill COVID-19 patients.</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-right: 3.6pt; font-weight: bold;">Information for Healthcare Facilities for Ordering GOHIBIC (vilobelimab)</div>
    <div style="text-align: justify; margin-right: 3.6pt;">Healthcare facilities can order GOHIBIC from ASD Healthcare (i) by calling 1-800-746-6273 or (ii) by e-mailing service@asdhealthcare.com. Please provide the product and notational drug code (NDC):
      GOHIBIC (NDC 83000-0110-04).</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-right: 3.6pt;">For detailed information about the Commitment Program and to file a claim, please visit this link: <u>The InflaRx Commitment Program</u>.</div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: justify; margin-right: 3.6pt;"><img width="149" height="47" src="image0.jpg"></div>
        </div>
      </div>
    </div>
    <div style="text-align: justify; margin-right: 3.6pt; font-weight: bold;">About the EUA for GOHIBIC (vilobelimab)</div>
    <div style="text-align: justify; margin-right: 3.6pt;">The FDA has issued an EUA for the emergency use of GOHIBIC for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of receiving IMV or ECMO.</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-right: 3.6pt;">GOHIBIC has not been approved but has been authorized for emergency use by FDA under an EUA for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of receiving IMV or
      ECMO.</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-right: 3.6pt;">The emergency use of GOHIBIC is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products
      during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. &#167; 360bbb-3(b)(1), unless the declaration is terminated, or authorization revoked sooner.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-right: 3.6pt; font-weight: bold;">Important Information about GOHIBIC (vilobelimab)</div>
    <div style="text-align: justify; margin-right: 3.6pt;">Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody that has been granted an EUA for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours
      of receiving IMV or ECMO.</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-right: 3.6pt;">Vilobelimab is an investigational drug that has not been approved by the FDA for any indication including for the treatment of COVID-19. There is limited information known about the safety and
      effectiveness of using GOHIBIC to treat people in the hospital with COVID-19.</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-right: 3.6pt;">Please see additional information in the Fact Sheet for Healthcare Providers, Fact Sheet for Patients and Parents/Caregivers and FDA Letter of Authorization on the GOHIBIC website <font style="color: rgb(68, 68, 68);">(</font><u>www.GOHIBIC.com</u><font style="color: rgb(68, 68, 68);">).</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-right: 3.6pt; font-weight: bold;">Important Safety Information about GOHIBIC (vilobelimab)</div>
    <div style="text-align: justify; margin-right: 3.6pt;">There are limited clinical data available for GOHIBIC. Serious and unexpected adverse events (AEs) may occur that have not been previously reported with GOHIBIC use.</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-right: 3.6pt;">GOHIBIC has been associated with an increase of serious infections. In patients with COVID-19, monitor for signs and symptoms of new infections during and after treatment with GOHIBIC.
      Hypersensitivity reactions have been observed with GOHIBIC. If a severe hypersensitivity reaction occurs, administration of GOHIBIC should be discontinued and appropriate therapy initiated.</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-right: 3.6pt;">The most common adverse reactions (incidence &#8805;3%) are pneumonia, sepsis, delirium, pulmonary embolism, hypertension, pneumothorax, deep vein thrombosis, herpes simplex, enterococcal infection,
      bronchopulmonary aspergillosis, hepatic enzyme increased, urinary tract infection, hypoxia, thrombocytopenia, pneumomediastinum, respiratory tract infection, supraventricular tachycardia, constipation, and rash.</div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: justify; margin-right: 3.6pt;"><img width="149" height="47" src="image0.jpg"></div>
        </div>
      </div>
    </div>
    <div style="text-align: justify; margin-right: 3.6pt;">Healthcare providers and/or their designee are responsible for mandatory FDA MedWatch reporting of all medication errors and serious adverse events or deaths occurring during GOHIBIC treatment and
      considered to be potentially attributable to GOHIBIC.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-right: 3.6pt; font-weight: bold;">Report side effects to the FDA at 1-800-FDA-1088 or <u>www.FDA.gov/medwatch</u>. In addition, side effects can be reported to InflaRx at: pvusa@inflarx.de</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-right: 3.6pt; font-weight: bold;">For the full prescribing information and additional important safety information, please visit <u>www.GOHIBIC.com</u></div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-right: 3.6pt; font-weight: bold;">About Viral Sepsis in SARS-CoV-2 Infection</div>
    <div style="text-align: justify; margin-right: 3.6pt;">Invasively mechanically ventilated patients who have tested positive for COVID-19 fulfill the criteria set by the current third international consensus definitions for sepsis, which define sepsis
      as a &#8220;life-threatening organ dysfunction caused by a dysregulated host response to infection&#8221;. Viral infection-mediated sepsis is believed to be driven by the inflammatory immune response of a patient to the virus. Observational studies have
      suggested that the inflammatory response, endothelial permeability and coagulopathy observed in severe COVID-19 are associated with strong complement activation and C5a generation as part of the human innate immune response. By targeting the
      complement component C5a in critically ill and invasively mechanically ventilated COVID-19 patients, vilobelimab is believed to block a key mediator of this inflammatory host response induced by severe SARS-CoV-2 infection and, thus, potentially
      offers a mechanism of action that may be independent of the viral variant that has caused such inflammatory response. Inhibition of the C5a / C5aR pathway has been demonstrated to be beneficial or lifesaving in various pre-clinical models of viral
      lung injury and viral sepsis, including models investigating influenza and corona viruses.</div>
    <div style="text-align: justify; margin-right: 3.6pt;"><br>
    </div>
    <div style="text-align: justify; margin-right: 3.6pt; font-weight: bold;">About Vilobelimab</div>
    <div style="text-align: justify; margin-right: 3.6pt;">Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards
      its target in human blood. Thus, vilobelimab leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism of the innate immune system, which is not the case for molecules blocking C5. In pre-clinical studies,
      vilobelimab has been shown to control the inflammatory response driven tissue and organ damage by specifically blocking C5a as a key &#8220;amplifier&#8221; of this response. In addition to development in COVID-19, vilobelimab is also being developed for various
      debilitating or life&#8209;threatening inflammatory indications, including pyoderma gangrenosum and cutaneous squamous cell carcinoma.</div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: justify; margin-right: 3.6pt;"><img width="149" height="47" src="image0.jpg"></div>
        </div>
      </div>
    </div>
    <div style="text-align: justify; margin-right: 3.6pt; font-weight: bold;">About InflaRx</div>
    <div style="text-align: justify; margin-right: 3.6pt;">InflaRx GmbH (in Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together InflaRx).</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-right: 3.6pt;">InflaRx (Nasdaq: IFRX) is a biotechnology company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize
      highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx&#8217;s lead product candidate,
      vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different
      indications. <font style="color: rgb(0, 0, 0);">InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit <u>www.inflarx.com</u>.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-right: 3.6pt; font-weight: bold;">Contacts</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="za1f87b1129f848c98e1758e5f70284b3" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 49.99%; vertical-align: top;">
            <div style="text-align: justify; margin-right: 3.7pt; font-weight: bold;">InflaRx N.V.</div>
          </td>
          <td style="width: 50.01%; vertical-align: top;">
            <div style="text-align: justify; margin-right: 3.7pt; font-weight: bold;">MC Services AG</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.99%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 50.01%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49.99%; vertical-align: top;">
            <div style="text-align: justify; margin-right: 3.7pt;">Email: <u>IR@inflarx.de</u></div>
          </td>
          <td style="width: 50.01%; vertical-align: top;">
            <div style="text-align: justify; margin-right: 3.7pt;">Katja Arnold, Laurie Doyle, Dr. Regina Lutz</div>
            <div style="text-align: justify; margin-right: 3.7pt;">Email: <u>inflarx@mc-services.eu</u></div>
            <div style="text-align: justify; margin-right: 3.7pt;">Europe: +49 89-210 2280</div>
            <div style="text-align: justify; margin-right: 3.7pt;">U.S.: +1-339-832-0752</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: justify; margin-right: 3.6pt;"><img width="149" height="47" src="image0.jpg"></div>
        </div>
      </div>
    </div>
    <div style="text-align: justify; margin-right: 3.6pt; font-weight: bold;">FORWARD-LOOKING STATEMENTS</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-right: 3.6pt;">This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as &#8220;may,&#8221;
      &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;believe,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; among others. Forward-looking statements appear in a number of places throughout this release and
      may include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, the receptiveness of Gohibic (vilobelimab) as a treatment for COVID-19 by COVID-19 patients and U.S.
      hospitals and related treatment recommendations by medical/healthcare institutes and other third-party organizations, our ability to successfully commercialize and the receptiveness of Gohibic (vilobelimab) as a treatment for COVID-19 by COVID-19
      patients and U.S. hospitals or our other product candidates; our expectations regarding the size of the patient populations for, market opportunity for, coverage and reimbursement for, estimated returns and return accruals for, and clinical utility
      of Gohibic (vilobelimab) in its approved or authorized indication or for vilobelimab and any other product candidates, under an Emergency Use Authorization and in the future if approved for commercial use in the United States or elsewhere; our
      ability to successfully implement the Commitment Program, the success of our future clinical trials for vilobelimab&#8217;s treatment of COVID-19 and other debilitating or life-threatening inflammatory indications, including pyoderma gangrenosum, and any
      other product candidates, including INF904, and whether such clinical results will reflect results seen in previously conducted pre-clinical studies and clinical trials; the timing, progress and results of pre-clinical studies and clinical trials of
      our product candidates and statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, the costs of such trials and our
      research and development programs generally; our interactions with regulators regarding the results of clinical trials and potential regulatory approval pathways, including related to our Marketing Authorization Application submission for vilobelimab
      and our biologics license application submission for Gohibic (vilobelimab), and our ability to obtain and maintain full regulatory approval of vilobelimab or Gohibic (vilobelimab) for any indication; whether the U.S. Food and Drug Administration, the
      European Medicines Agency or any comparable foreign regulatory authority will accept or agree with the number, design, size, conduct or implementation of our clinical trials, including any proposed primary or secondary endpoints for such trials; our
      expectations regarding the scope of any approved indication for vilobelimab; our ability to leverage our proprietary anti-C5a and C5aR technologies to discover and develop therapies to treat complement-mediated autoimmune and inflammatory diseases;
      our ability to protect, maintain and enforce our intellectual property protection for vilobelimab and any other product candidates, and the scope of such protection; our manufacturing capabilities and strategy, including the scalability and cost of
      our manufacturing methods and processes and the optimization of our manufacturing methods and processes, and our ability to continue to rely on our existing third-party manufacturers and our ability to engage additional third-party manufacturers for
      our planned future clinical trials and for commercial supply of vilobelimab and for the finished product Gohibic (vilobelimab); our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain
      additional financing; our ability to defend against liability claims resulting from the testing of our product candidates in the clinic or, if approved, any commercial sales; if any of our product candidates obtain regulatory approval, our ability to
      comply with and satisfy ongoing obligations and continued regulatory overview; our ability to comply with enacted and future legislation in seeking marketing approval and commercialization; our future growth and ability to compete, which depends on
      our retaining key personnel and recruiting additional qualified personnel; and our competitive position and the development of and projections relating to our competitors in the development of C5a and C5aR inhibitors or our industry; and the risks,
      uncertainties and other factors described under the heading &#8220;Risk Factors&#8221; in our periodic filings with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks,
      uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given
      these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future,
      except as required by law.</div>
    <div>&#160;</div>
    <div> <br>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '=!=P# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?Z+]0HHHK8^."BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD) !). .I
M- "T5RNL>.;&Q+160^US#C(.$'X]_P /SKAM2\1:IJI87%TPC/\ RRC^5/R[
M_CF@#TR^\3Z/IY*RWB-(/X(OG/Z=/QKGKOXBQ D6=@S#^],^/T&?YUP%%,1T
M]QX\UF;_ %9@@_W(\G_Q[-9\OBC6Y?O:E,/]PA?Y5D44 7&U?4W.6U&[/UF;
M_&HSJ%Z>MW<'ZR'_ !JO10!;75-03[M_=+])F_QJ9-?UB,Y74[O_ (%,Q_G6
M=10!OP^--=BZW8D'H\:G^F:T[7XB7J8%U9P2CUC)0_UKC:* /3;3Q]I,Y"SI
M/;D]2R[E_,<_I70VE_:7Z;[2YBF'?8P)'U':O$:FM1*UW"D#LDKN%4J<$$G%
M 'N-%(J[45<DX&,DY)I:0PHHHH H:GK5AHXB-],8_-SLPA;.,9Z#W%9W_":Z
M#_S^-_WY?_"N8^(=QOU:VMP>(H=Q^K$_X"N/H ]7_P"$UT'_ )_&_P"_+_X4
M?\)KH/\ S^-_WY?_  KRBBF(]7_X370?^?QO^_+_ .%'_":Z#_S^-_WY?_"O
M*** /5_^$UT'_G\;_OR_^%'_  FN@_\ /XW_ 'Y?_"O*** /5_\ A-=!_P"?
MQO\ OR_^%;=M<17=M'<0L6BD4,I((R#]:\. +, !DDX KW"T@%M9P6XZ11J@
M_ 8I#)J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***I:Q?#2]#O\ 4#TM
M;:28Y_V5)_I0!R4_QA\$6]Q)!)J[B2-RC 6LI&0<'G;4?_"Y_ O_ $%Y/_ 2
M7_XFOE<DLQ8DDDY)-)3&?5/_  N?P+_T%Y/_  $E_P#B:/\ A<_@7_H+R?\
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M]O\ 9/'TKZ2T/7-.\1:5%J6EW*SVT@X(ZJ>ZL.Q'I2$:-%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !65XCUN#P[H5SJ4^#Y2_(F?ON>%7\_TS6K7
MB7Q?UXW>MPZ-$_[FS4/* >#(P_HN/S-3.7*KGHY5@OKF*C3>V[]%_5C@-1U"
MYU;49[^\D,EQ.Y9V_H/8=!56BBN4_3XQ44HQT2"BBB@84444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "OG?\ :#U#SO%.EV .1;6AD/L78_T05]$5\G?%O4/[0^)FKL#E
M(76!?;8H!_\ 'LT <31113&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB@ HHJ6UA-S=PP#K+(J#\3B@#V'0;?[+H%C#C!$*DCW(R?U-:-(JA5"J, #
M%+2&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 (2%4DD  9)-?$^LWQU37
M-0U DDW5S)-S_M,3_6OKSQGJ']E^"=:O0<-'9R[#_M%2%_4BOC6@ HHHIC"B
MBB@ HHHH **** "BGB&4C(C<@_[)I?(E_P">3_\ ?)H CHJ3R)?^>3_]\FCR
M)?\ GD__ 'R: (Z*D\B7_GD__?)IA!!P00?0T )1110 4444 %%%% !1110
M4444 %%%% !7T-\"?%_]H:1-X;NY,W%B/,MMQY:$GD?\!)_)AZ5\\UN>#]>?
MPSXLT[5E)V03#S0/XHSPX_[Y)H ^RZ*;'(DL:R1L&1P&5@>"#T-.I""BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH Y;XC GP!JV.NQ/_ $-:^<J^G?%MH;[PCJUN
MHRS6LA4>I R/U%?,585=S[GA:2>&G'M+]%_D%%%%9'U 4444 %%%% !1110
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M_P .U8=,84444 %%%% !1110 4444 ?67PGU<ZQ\.-+=WW2VRFUDYZ;#A?\
MQW;7:UXI^SQ?E]-US3BWRQ31SJO^\"I_] 6O:Z0@HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ IDL4<\+PRHKQNI5U89# ]0:?10"=CY\\>>!I_#%\US:H\FE3-^[?KY1/\
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MK8>9.^#/<$8:1OZ =A6_116Z5CX6K5G6FZE1W;"BBBF9A1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ J"]NDLK&XNY/\ 5P1-*WT49/\
M*IZY+XG:A_9OPVUR;."]N8!_VT(3_P!FH ^29YGN+B2>0YDD8NQ]23DU'113
M&%%%% !1110 4444 %?4GP3T_P"P_#6TE(PUY/+.?^^M@_1!7RW7V=X1T_\
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MO_LU>IUP/PYM\S7UR1]U5C!^N2?Y"N^I#"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHJO/?6EK_P ?%U!#_P!=) O\Z +%%8D_BW0[?[U^CGTC4M_(
M8K.E^(.DH<)#=2>X10/U- '645QC?$6S'W+&<_5@*A;XCIGY=+8_6?'_ ++0
M!W-%<,/B/'WTQA])O_L:D7XC6V?FT^4?20'^E ':T5R*?$/2S]^VNU^BJ?ZU
M9B\=:))]Z2:/_?B/],T =+161%XHT2;[NHPC_?RO\P*T(+VUN?\ CWN89?\
MKG(&_E0!/1110 4444 %%%% !1110 4444 %>4_'W4/L_@BULU.&NKQ<CU55
M8G]=M>K5X!^T-J&_6-%TX'_4P23D?[[!1_Z : /%Z***8PHHHH **** "BBB
M@#1\/Z?_ &KXCTS3\9%U=1PGZ,P!K[6KY3^#NG_;_B9IA(REL))V_P" J<?^
M/%:^K*0@HHHH **** "BBB@ HHHH **** "OD#XC7HO_ (BZ].&W 7;1 _[G
MR?\ LM?6VHWL6FZ9=W\YQ%;0O,Y]E!)_E7Q+<3R7-S+<2G,DKEV/J2<F@".B
MBBF,**** "BBB@ HHHH ]\_9WM-NFZ[>D?ZR:*('_=#$_P#H8KVNO/?@MIO]
MG_#6SD*X>\EDN&'U;:/T05Z%2$%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %87B_Q59>#_#\^J7IW%?EAA!P99#T4?U/8 UK7EY;Z?937
MEW,L-O ADDD<X"J.2:^3OB'XXN/&WB%KCYH]/@REI"?X5[L?]INI_ =J .B/
MQ[\7Y.(-+ ]/(;_XND_X7UXO_P">.E_]^&_^+KR^BF,]0_X7UXO_ .>.E_\
M?AO_ (NC_A?7B_\ YXZ7_P!^&_\ BZ\OHH ]0_X7UXO_ .>.E_\ ?AO_ (NC
M_A?7B_\ YXZ7_P!^&_\ BZ\OHH ]0_X7UXO_ .>.E_\ ?AO_ (NC_A?7B_\
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M?M_M7B"PBQD&96(]AR?T%9M=1X"M_.\1>:1Q#"S9]SA?ZF@#T^BBBD,****
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M<O.1_N+C_P!J5\_5ZQ\?M0^T>-+.R4Y6ULP2/1G9B?T"UY/3&%%%% !1110
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M4)KZ_N)+BZF;=)(YR2?\/;M56BF,**** "BBB@ HHHH **** "OI3X,>!/\
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M3T3P_9Z) %A0/.1\\S#YF_P'M4NC:/;Z+8+;0#+'F20CEV]?_K5HTAA1110
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M3^,[C[1XGN0#E8@L8_ #/ZDU@5:U*X^UZI=7&<B69G'T)JK3$%%%% !1110
M4444 7-*M_M>KV=OC(DF13],\_I7M=>4^";?S_$\#$9$2M(?RP/U(KU:D,**
M** "BBB@!LCI%&TDC!44%F8] !7D'B+67UK57G!(@3Y(5/9?7ZGK76>/=:,,
M*Z5 V&E&^8CLO8?C_GK7GM,04444 %%%% !1110 445;TS3I]5OXK2W&7<\G
MLH[D^U %C0]$N-<O?(A^6->9)2.$'^/M7J^F:7:Z19K;6L>U1RS'[SGU)HTK
M2[;2+%+6V7@<LQZN>Y-7:0PHHHH **** "BBB@ KR/Q=<?:/$]X0>$81C\
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M[)I%Y<9P8X78?7'%7*Y[QM<>1X8G4'!E98Q^>3^@- 'E-%%%,04444 %%%%
M!1110!V_PZM\W5]<D?<18P?J<G_T$5Z!7*> +?RM!DF(YFF)!]@ /YYKJZ0P
MHHHH *AN[J*RM);F8XCB4LQ^E35P_P 0=4*10:9&W^L_>RX]!]T?GD_@* .)
MU"]EU&_FNYC\\K%B/0=A^ XJM113$%%%% !1110 4444 '4X%>K>$]!71].$
MDJ?Z9. TA/51V7_'WKDO!&BC4-2-Y,N8+4@@'HS]ORZ_E7IU(84444 %%%%
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M%%% !1110 5YK\0;CS-<A@!XBA&?J23_ "Q7I5>/^*+C[3XFOGSD+)Y8_P"
MC;_2@#(HHHIB"BBB@ HHHH **** "IK6VEO+J*VA7=)*P51[FH:[CX?Z2'EF
MU25>$_=PY]?XC^7'XF@#M=-L(M,TZ"SA^[$N,^I[G\35JBBD,**** "BBB@
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MNOHH ^&**[OXM^%_^$:\;W!ACVV5_FY@P.!D_.OX-GCT(KA*8PHHHH ****
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MR?4#I[<>F?:J^&X9I;>>.>&1HY8V#HZ'!5@<@@^M?5OPR\=1^-?#P,Y5=4M
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M(7VEX'GE?,MF/\,J\K],]#[$T ?'=%.DC>&5XI$*2(Q5E88((Z@TVF,****
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M .RT >@T444AA1110 5Y[\1;C=?65MG[D;2'_@1Q_P"RUZ%7D_C.X^T>)[D
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M HHHH **** /6?!@QX4L_?>?_'VK>K$\(@#PK8X_NM_Z$:VZ0PHHHH ****
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M.?-E9Q]":]BU:X^R:/>3YP8X6(^N./UKQ2@ HHHIB"BBB@ HHHH *W?!]O\
M:/$]ID96,M(?P!Q^N*PJ[/X=V^_4KRYQ_JX@G_?1S_[+0!Z)1112&%%%% !1
M110 4444 %%%% !1110 5@>,[C[/X8N@#AI2L8_$C/Z UOUQ?Q%N-MA96V?]
M9*7/_ 1C_P!FH \\HHHIB"BBB@ HHHH **** /2OA];^7HDTY',LQQ] !_7-
M=;6/X6M_LWAFQ3&"T?F'_@1+?UK8I#"BBB@ KR#Q4V[Q/?G_ *:8_("O7Z\>
M\3C'B:_'_37/Z4 9-%%%,04444 %%%% !1110!ZSX,;=X4L_52X/_?;5O5R7
MP^N!)H<T.?FBG/'L0,?KFNMI#"BBB@ HHHH ***Q/$VOQZ)8'80;N48B3T_V
MC["@#G_'>NC TBW?GAK@@_DO]3^%<'3I)'ED:21BSN2S,3R2:;3$%%%% !11
M10 4444 %%%% !7J/@2'RO#2OC_6RN_\E_I7EU>P^&8?(\-:>F,9B#_]]?-_
M6@#6HHHI#"BBB@ KYI^/-_\ :O'T5J#\MI9HA'HS$L?T*U]+5\@?$;4/[3^(
MFNW&<@7;1 ^HC^0?^@T <O1113&%%%% !1110 4444 >G? BP^U_$%KDKQ9V
MDD@/HQPG\F-?3->(?L[Z?BVUS46'WGB@0_0,S?S6O;Z0@HHHH **** "BBB@
M KY0^*_A?_A&/'%TL,>VRO?]*M\#@;C\R_@V>/0BOJ^O.OC-X7_X2#P5)>01
M[KS3";A,#DQX_>#\AN_X#0!\NT444QA1110 4444 %%%% &SX4U^;PQXGL-8
MAR?L\@,B#^-#PR_B":^R+6ZAO;.&[MI!)!/&LD;CHRD9!_*OAZOH[X$^*?[3
M\-S:#<29N=..Z+)Y:%CQ_P!\MD?0K0!ZS1112$%%%% !1110 4R66."%YIG6
M.*-2SNQP% Y))["GU\_?&/XD_P!H32^&-&G_ -$C;%[.A_UK#^ '^Z#U]3[#
MD YOXI?$23QCJOV.Q=ET6U<^4O3SFZ>81_(=A]37GM%%,84444 %%%% !116
MOX9\.WOBK7K;2;!<RS-\SD?+&@ZL?8?X#O0!L>"_A_J?C.WU*YM@8X+.!BKE
M?];-C*QCW/<]N/45R'0X-?:GA[0;+PSH=MI.GQ[8(%QD]7;NQ]R>:^8?BMX<
M_P"$<\>WL<:;;6\/VJ# XPQ.X?@VX?3% '$T444 %%%% !1110 5WOPC\4_\
M(UXV@2:3;9:ABVGR> 2?D;\&_0FN"HH ^YZ*X_X9>*?^$K\%6EU+)NO;<?9[
MK)Y+J!\W_ A@_4FNPI""BBB@ HHHH **** "BBB@ HHHH *XGXBW&VTL;8'[
M\C2$?08_]F-=M7F?Q N/-UZ.$'B&$ CW))_EB@#E****8@HHHH **** "BBG
M(C2.J*,LQ  ]Z /7?"UO]F\,V*8P6C\P_P# B6_K6Q4<$2P6\4*_=C0(/H!B
MI*0PHHHH **** "O(?%=Q]I\3WS9X5Q&/^ @#^8->NLP52S'  R37AUS,;F[
MFG;K([.?Q.: (J***8@HHHH **** "I[*W-W?V]L.LLBI^9Q4%=!X+M?M/B:
MW)&5A5I#^ P/U(H ]650JA5& !@"EHHI#"BBB@ HHHH **** "BBB@#R[QW<
M>=XE>//^IB1/_9O_ &:N9K1UZX^U:_?39R#,P!]@<#]!6=3$%%%% !1110 4
M444 .CC:65(U&6=@H^IKW*&-888XE^ZBA1]!7D'ANW^U>(["/&0)0Y_X#\W]
M*]BI#"BBB@ HHHH YWQO<>1X8F7.#,ZQC\\_R!KRJN_^(UQBWL;8'[SM(1]
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M(N[R613_  9POY#BJ%%% !1110 5HZ)I4FL:K#:)D*3ND8?PJ.I_SZUG $G
M&2:]7\)Z"-'TW?,O^ES@-)_LCLO^/O0!A_$"1+>ST[3X5"QKE@H[   ?S-<)
M75>/YO,\0)&#Q% HQ[DD_P!17*T %%%% !1110 4444 ;?A&+SO%%BIZ*S/^
M2D_TKURO+_ <>_Q(&_YYPNW\A_6O4*0PHHHH **** /*_CWJ'V;P+;VBGYKN
M\12/55#,?U"U\V5[5^T/?[]4T33@?]5#).P_WF"C_P! ->*TQA1110 4444
M%%%% !5W1[$ZGK=AIZ];JYCA&/\ :8#^M4J[;X2V']H?$S1U(RD+M.WML4D?
M^/8H ^L  JA5   P *6BBD(**** "BBB@ HHHH **** (;NUAOK*>SN8Q)!/
M&T<B'HRL,$?D:^-?%&A3^&?$M_H\^2UM*55B/OH>5;\5(-?:%>)?'[POYMK9
M^)K>/YH<6UU@?PDY1C]#D?\  A0!X+1113&%%%% !1110 4444 =A\,_%/\
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M5]A>/_#H\4>"M1TU4W7!C\VW_P"NJ\K^?3Z$U\>D$'!&".HIC"BBB@ HHHH
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M@C'LSL/Z(:\@KZ(_9\L/)\+:I?D8-S=B,>X10?YN: /7Z***0@HHHH ****
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M]?H: .^^$?P_'A71O[3U"+&KWJ L&',$?4)]3P3^ [5Z3112$%%%% !1110
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M*>X->0:]HTNB:F]N^6B/S1/_ 'E_Q]:]CK-UO1K?6[!K>8;7',<@'*-_A[4
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M*]N_LZQ_Y\[?_OTO^%']G6/_ #YV_P#WZ7_"F!XC17MW]G6/_/G;_P#?I?\
M"C^SK'_GSM_^_2_X4 >(T5[=_9UC_P ^=O\ ]^E_PH_LZQ_Y\[?_ +]+_A0!
MY?X-M_M'B>UR,K&&D/X X_4BO6:ABM+:!]\5O%&V,91 #4U( HHHH **** "
ML3Q=<?9O#%X0>741C\2 ?TS6W3)8HYDV2QI(N<X=010!X717MW]G6/\ SYV_
M_?I?\*/[.L?^?.W_ ._2_P"%,#Q&BO;O[.L?^?.W_P"_2_X4?V=8_P#/G;_]
M^E_PH \1HKV[^SK'_GSM_P#OTO\ A1_9UC_SYV__ 'Z7_"@#Q&BO;O[.L?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK^WU33;:_M'WV]S$LL;>JD9%6:0@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%>"?'[POY5W9^)K>/Y9L6UU@?Q 91C]1D?\  17O=8GB_1[?7O"6IZ==#]W+
M Q#8R59?F5OP(!H ^,Z***8PHHHH **** "BBB@ KZ2^!GBG^UO"TFBW$F;K
M3#A,GEH6^[^1R/IMKYMKL/A=K-SHWQ#TE[<Y6ZF6TE7. R2$#]#@_4"@#ZWH
MHHI""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
1HH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
